Download PDF
Thromb Haemost 2001; 86(02): 590-595
DOI: 10.1055/s-0037-1616091
Review Article
Schattauer GmbH

β2-glycoprotein I-dependent Anticardiolipin Antibodies Preferentially Bind the Amino Terminal Domain of β2-glycoprotein I

Patricia A. McNeeley
1   La Jolla Pharmaceutical Company, San Diego, CA
,
Jeffrey S. Dlott
2   Midwest Hemostasis and Thrombosis Laboratories, Medical Education Department, Ball Memorial Hospital, Muncie, IN
,
Richard A. Furie
3   Division of Rheumatology and Allergy-Clinical Immunology, North Shore University Hospital-NYU School of Medicine, Manhasset, NY
,
Richard M. Jack
4   Triad Therapeutics, San Diego, CA
,
Thomas L. Ortel   *
5   Department of Medicine, Duke University Medical Center, Durham, NC, USA
,
Douglas A. Triplett
2   Midwest Hemostasis and Thrombosis Laboratories, Medical Education Department, Ball Memorial Hospital, Muncie, IN
,
Edward J. Victoria
1   La Jolla Pharmaceutical Company, San Diego, CA
,
Matthew D. Linnik   *
1   La Jolla Pharmaceutical Company, San Diego, CA
› Author Affiliations
Further Information

Publication History

Received 18 December 2000

Accepted after revision 16 March 2001

Publication Date:
12 December 2017 (online)

    Permissions and Reprints

Summary

Many of the autoantibodies in antiphospholipid syndrome (APS) are directed against β2-glycoprotein I (β2-GPI). Recent studies from our laboratories have indicated that the immunodominant binding epitope(s) for high titer, affinity purified antibodies from 11 APS patients are localized to the amino terminal domain (domain 1) of β2-GPI. The present study employed surface plasmon resonance to localize the immunodominant domain in serum samples from a large cohort of patients with GPL values ranging from 21 to 230 units (n = 106 patients). Eighty-eight percent of patients showed ≥ threefold selectivity for β2-GPI containing domain 1 relative to the domain deletion mutant that lacked domain 1. The domain 1 binding activity in patient serum was abolished by removing the IgG fraction from the serum and the binding activity could be fully reconstituted with the IgG fraction. Thus, analysis of serum samples from a large cohort of APS patients indicates that the immunodominant binding epitope(s) for anti- 2 antibodies are localized to the amino terminal domain of β2-GPI.

Keywords

Anticardiolipin antibodies - antiphospholipid syndrome - β2-glyco-protein I

* TLO is supported by a Research Grant from the Arthritis Foundation and a Midcareer Investigator Award in Patient-Oriented Research (1 K24 AI01603-01) from the NIH.


 

  • References

  • 1 Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983; 287: 1088-9.
    CrossrefPubMedGoogle Scholar
  • 2 Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-4.
    CrossrefPubMedGoogle Scholar
  • 3 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
    CrossrefPubMedGoogle Scholar
  • 4 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van-BredaVriesman PJ, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a serum protein cofactor. Lancet 1990; 335: 1544-7.
    CrossrefPubMedGoogle Scholar
  • 5 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.
    PubMedGoogle Scholar
  • 6 Kato H, Enjyoji K. Amino acid sequence and location of the disulfide bonds in bovine beta 2 glycoprotein I: the presence of five sushi domains. Biochemistry 1991; 30: 11687-94.
    CrossrefPubMedGoogle Scholar
  • 7 Hunt J, Krilis SA. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 653-9.
    PubMedGoogle Scholar
  • 8 Del Papa N, Sheng YH, Raschi E, Kandiah DA, Tincani A, Khamashta MA, Atsumi T, Hughes GRV, Ichikawa K, Koike T, Balestrieri G, Krilis SA, Meroni PL. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol 1998; 160: 5572-8.
    PubMedGoogle Scholar
  • 9 Igarashi M, Matsuura E, Igarashi Y, Nagae H, Ichikawa K, Triplett DA, Koike T. Human β2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system. Blood 1996; 87: 3262-70.
    PubMedGoogle Scholar
  • 10 Koike T, Matsuura E. Anti-beta 2-glycoprotein I antibody: specificity and clinical significance. Lupus 1996; 5: 378-80.
    CrossrefPubMedGoogle Scholar
  • 11 Koike T, Ichikawa K, Kasahara H, Atsumi T, Matsuura E. Epitopes on β2-GPI recognized by anticardiolipin antibodies. Lupus 1998; 7: S14-7.
    CrossrefPubMedGoogle Scholar
  • 12 Hunt JE, Simpson RJ, Krilis SA. Identification of a region of β2-glyco-protein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141-5.
    CrossrefPubMedGoogle Scholar
  • 13 Yang CD, Chen SL, Shen Qi M, Xu F. Detection of anti-recombinant β2-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus. Rheumatol Int 1998; 18: 5-10.
    CrossrefPubMedGoogle Scholar
  • 14 Wang MX, Kandiah DA, Ichikawa K, Khamashta M, Hughes G, Koike Roubey SA. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol 1995; 155: 1629-36.
    PubMedGoogle Scholar
  • 15 Iverson GM, Victoria EJ, Marquis DM. Anti- β2 glycoprotein I (β2-GPI) autoantibodies recognize an epitope on the first domain of β2-GPI. Proc Natl Acad Sci USA 1998; 95: 15542-6.
    CrossrefPubMedGoogle Scholar
  • 16 Iverson GM, Jones DS, Marquis D, Linnik MD, Victoria EJ. A chemically defined, toleragen-based approach for targeting anti-β2-glycoprotein I antibodies. Lupus 1998; 7: S166-9.
    CrossrefPubMedGoogle Scholar
  • 17 Harris EN. Antiphospholipid antibodies. Annotation. Brit J Haematol 1990; 74: 1-9.
    PubMedGoogle Scholar
  • 18 Sem DS, McNeeley PA, Linnik MD. Antibody affinities and relative titers in polyclonal populations: surface plasmon resonance analysis of anti-DNA antibodies. Arch Biochem Biophys 1999; 372: 62-8.
    CrossrefPubMedGoogle Scholar
  • 19 Stenberg E, Persson B, Roos H, Urbaniczky C. Quantitative determination of surface concentration of protein with surface plasmon resonance by using radiolabeled proteins. J Colloid Inter Sci 1991; 143: 513.
    CrossrefPubMedGoogle Scholar
  • 20 George J, Gilburd B, Hojnik M, Levy Y, Langevitz P, Matsuura E, Koike T, Shoenfeld Y. Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding. J Immunol 1998; 160: 3917-23.
    PubMedGoogle Scholar
  • 21 Bouma B, deGroot PG, vanden Elsen JMH, Ravelli RBG, Schouten A, Simmelink MJA, Derksen RHWM, Kroon J, Gros P. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-74.
    CrossrefPubMedGoogle Scholar
  • 22 Arvieux J, Roussel B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I. Thromb Haemos. 1993; 70: 336-41.
    PubMedGoogle Scholar
  • 23 Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by beta 2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 342-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Vazquez-Mellado J, Llorente L, Richaud-Patin Y, Alarcon-Segovia D. Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun 1994; 7: 335-48.
    CrossrefPubMedGoogle Scholar
  • 25 Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo . Circulation 1999; 15: 1997-2002.
    PubMedGoogle Scholar
  • 26 Galli M, Duca F, Ruggeri L, Finazzi G, Begri B, Moia M. Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays. Thromb Haemost 1998; 80: 246-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Merrill JT, Zhang HW, Shen C, Butman BT, Jeffries EP, Lahita RG, Myone BL. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its serum inhibitor, C4b-binding protein. Thromb Haemost 1999; 81: 748-57.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Rand JH, Wu XX, Andree HA, Ross JB, Rusinova E, Gascon-Lema MG, Calandri C, Harpel PC. Antiphospholipid antibodies accelerate serum coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood 1998; 92: 1652-60.
    PubMedGoogle Scholar
  • 29 Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90: 1100-4.
    CrossrefPubMedGoogle Scholar
  • 30 Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG.. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost 1992; 67: 499-502.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Regnault V, De Maistre E, Wahl D, Lecompte T. Monovalent binding of autoantibodies to B2-glycoprotein I, detected using surface plasmon resonance at low antigen density. Brit J Haemoto. 2000; 109: 187-94.
    PubMedGoogle Scholar
  • 32 Sem DS, Baker BL, Victoria EJ, Jones DS, Marquis D, Yu L, Parks J, Coutts SM. Structural characterization and optimization of antibody-selected phage library mimotopes of an antigen associated with autoimmune recurrent thrombosis. Biochemistry 1998; 37: 16069-81.
    CrossrefPubMedGoogle Scholar
  • 33 Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, KatchalskiKatzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999; 96: 5164-8.
    CrossrefPubMedGoogle Scholar
  • 34 Jones DS, Coutts SM, Gamino CA, Iverson GM, Linnik MD, Randow ME, Ton-Nu HT, Victoria EJ. Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response. Bioconjug Chem 1999; 10: 480-8.
    CrossrefPubMedGoogle Scholar